In conclusion, KPT-9274 demonstrated a promising activity against NAMPT or PAK4-driven cancer growth, suggesting it is a potential novel treatment for platinum-resistant ovarian cancer. This evidence concerns the gene NAMPT and ovarian carcinoma.